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Objective: The use of intravascular stents in the superficial femoral artery (SFA) continues to be controversial due to the
potential for compression and fracture in the tortuous physical environment of the adductor canal. The purpose of this
studywas to (1) characterize the types and ranges of stent distortion theoretically produced by extremitymovement and (2) use
these ranges as parameters for in vitro long-term fatigue testing of commercially available self-expanding nitinol stents.
Methods: Nitinol self-expanding stents were placed in the SFAs of cadavers and lateral view radiographs were obtained
with the limb in various degrees of hip and knee flexion. The measured degrees of axial shortening and bending of the
stent were estimated by planimetry and used for in vitro fatigue testing, which was undertaken using specially designed
equipment. Six different commercially available nitinol self-expanding stents—Protégé EverFlex (EV3, Minneapolis,
Minn), S.M.A.R.T. Control (Cordis/Johnson & Johnson, Miami Lakes, Fla), Luminexx (C.R. Bard, Murray Hill, NJ),
LifeStent FlexStar (Edwards Lifesciences, Irvine, Calif), and Xceed and Absolute (Abbott Vascular, Santa Clara,
Calif)—were mounted in elastic silicone tubing, bathed in phosphate buffered saline at 37°  2°C, and examined for
fracture after 10 million cycles of chronic deformation.
Results: For unstented arteries, the distal SFA/proximal popliteal artery exhibited the greatest axial compression (23%) vs
the middle SFA (9%) or popliteal artery (14%) at 90°/90° knee/hip flexion. For stented arteries, the popliteal artery
exhibited the most axial compression (11%) vs the middle SFA (3%) or distal SFA/proximal popliteal artery (6%) at
90°/90° knee/hip flexion. Axial compression of the stented popliteal artery at 70°/20° knee/hip flexion was 6% with a
deflection angle of 33°. These parameters were used for chronic in vitro fatigue testing, which produced a range of
responses in commercially available stents. Chronic 5% axial compression resulted in high rates of fracture of Luminexx
(80%) and LifeStent FlexStar (50%), with lower fracture rates for Absolute (3%), Protégé EverFlex (0%), and S.M.A.R.T.
Control stents (0%). Chronic 48° bending deformation resulted in high rates of fracture in Protégé EverFlex (100%),
S.M.A.R.T. Control (100%), and Luminexx stents (100%), with lower rates in Absolute (3%) and LifeStent FlexStar (0%).
Conclusion: Nitinol self-expanding stents undergo both axial and bending deformation when implanted into the
superficial femoral and popliteal arteries. Commercially available stents exhibit a variable ability to withstand chronic
deformation in vitro, and their response is highly dependent on the type of deformation applied. (J Vasc Surg 2008;48:
435-40.)
Clinical Relevance: The use of stents in the superficial femoral artery continues to be controversial because many believe
that the biomechanical forces exerted on the vessel through standing and walking are unfavorable to chronically
indwelling devices. The purpose of this study was to (1) use a human cadaver model to characterize the types and ranges
of stent distortion produced by extremity movement and (2) use these ranges as parameters for in vitro fatigue testing of
commercially available self-expanding stents. These results show that stents are indeed subjected to measurable axial and
bending deformation in the cadaveric superficial femoral artery and that currently available stents exhibit a variable ability
to withstand chronic deformation depending on stent design and the type of deformation applied.Occlusive atherosclerotic lesions in the femoropopliteal
artery are notoriously difficult to treat endovascularly. Al-
though technical success rates have recently approached
95%,1,2 intermediate-term restenosis and failure complicate
up to 50% of interventions in complex lesions and occlu-
sions.3-10 Several procedural adjuncts designed to improve
patency have been suggested, including atherectomy, cryo-
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doi:10.1016/j.jvs.2008.02.029plasty, and intraluminal stenting.8,11-13 Stenting has be-
come increasingly applied, given the recent demonstration
of its superiority over simple percutaneous angioplasty in a
randomized trial.14 In-stent restenosis remains a significant
clinical problem, however, as this same study found reste-
nosis in 46% of stented patients at 2 years.
The reasons for the high rate of restenosis in stented
femoropopliteal arteries have not been fully elucidated.
One hypothesis is that in-stent restenosis may be a function
of the unique biomechanical forces present in stented in-
frainguinal arteries.15 These forces create repetitive trauma
to the stent and artery, resulting in segmental bending,
compression, and kinking, which are known stimulators of
inflammation and smooth muscle cell activation. It is rea-
sonable to conclude that these forces, known to perturb
stent structure and integrity, may also serve as nidi for
arterial disruption and restenosis.16,17 This study was de-
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formations of femoropopliteal stents during extremity
movement. Its specific purpose was to (1) characterize the
types and ranges of stent distortion theoretically produced
by extremity movement and (2) use these ranges as param-
eters for in vitro long-term fatigue testing of commercially
available self-expanding nitinol stents.
METHODS
Assessment of native (unstented) arterial deforma-
tion in cadaveric lower extremity arteries. Arterial de-
formation was assessed in a cadaver model wherein speci-
mens had been preserved so as to enable establishment of
warm (body temperature) saline through the vasculature to
simulate blood flow using methods described elsewhere.18
This method of preservation retains flexibility of vessels and
muscles and permits simulation of natural movement of the
limb. Eight cadavers were used in this study.
Cadavers were placed in a supine position and guide
catheters were introduced through antegrade access to the
common femoral artery. Angiography of arteries confirmed
vessel patency and condition. Short sections of balloon
expandable stents were placed in the arterial lumen proxi-
mal and distal to the area of measurement to serve as
radiopaque reference points. Lateral view radiographs were
taken for measurement at (1) the neutral position (straight
leg, assuming 0° or no flexion in knee and hip joints), (2)
knee flexion of 70° (bending angle of 110°) and hip flexion
of 20° (bending angle of 160°), and (3) knee and hip
flexion of 90°. The 70°/20° position was meant to repre-
sent walking; the 90°/90° position was meant to represent
sitting-to-standing or stair climbing. These angles were
shown previously to be appropriate approximations of neu-
tral (straight leg), walking, and stair climbing leg positions
during motion.19
Assessment of self-expanding stent deformation in
cadaveric lower extremity arteries. Stents of 100 mm
length, Absolute 0.035 Biliary Self-Expanding Stent Sys-
tem stents (Abbott Vascular, Santa Clara, Calif) were de-
ployed in the superficial femoral artery (SFA) or popliteal
artery (PA), or in both arteries of cadavers and postdilated
with a balloon catheter to ensure good apposition to the
arterial wall and to simulate the clinical setting. For the
purpose of measurement, the artery was separated into
three segments: middle SFA (mid-SFA); distal SFA/prox-
imal PA (distal-SFA/prox-PA); and the PA. The bound-
aries of the SFA were defined (proximally) as 1 cm from the
femoral bifurcation and (distally) as 3 cm from the proximal
margin of the intercondylar fossa of the femur. Stents were
defined as being located in the “mid-SFA” when entirely
confined to this segment, in the “distal-SFA/prox-PA”
when themajor portion of the 100-mm stent was located in
the distal-SFA and there was limited extension into the PA,
and in the “PA” when the major portion of the stent was
retrogeniculate.
Images were obtained in the lateral view to facilitate
assessment of artery and stent behavior during knee and hip
flexion. For each implanted stent, the lengths at neutral(0°), flexion of 70/20°, and flexion of 90/90° were deter-
mined. The primary measurements from the lateral view
images were of stent shortening (edge-to-edge) and deflec-
tion angle, defined as the bend angle between neutral
(defined as 0°) and flexion (Fig 1).
For subsequent stent fatigue testing of axial compression,
the average between the distal-SFA/prox-PA and the PA at
70/20° knee/hip flexion was selected (5%) because it repre-
sents walking, which is a more frequent repetitive motion. A
48° bending angle test parameter was selected for fatigue testing
of bending stress because it represented theupper rangeof values
observed in the PA at 70°/20° knee/hip flexion.
Assessment of fracture after repetitive in vitro axial
compression. Repetitive axial compression was performed
using a specially designed axial fatigue test machine wherein
stents were housed in elastic silicone tubing with 3.0 0.2
mm wall thickness (Fig 2). The tubes were loaded into the
Fig 1. Measurement of stent shortening and bending was tested
in cadaveric femoropopliteal arteries. A, A radiograph shows the
stent in a leg in neutral position. The bending angle (°) and stent
length (L) are labeled. B, A radiograph shows the stent at knee/
hip flexion 90°/90°. Axial compression was determined by sub-
traction of the measured data at flexed position from the data at
neutral position and deflection angle by subtraction of the data at
neutral position from the data at flexed position.machine and stretched axially 5% before stent deployment,
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after deployment. Stents were deployed into the tubing
with an oversize ratio of 1:1.4. Phosphate-buffered saline
(37°  2°C) was circulated through the closed system for
the duration of the experiment. The fatigue tester was set to
cycle at 10Hz for a total of 10million cycles. The stents were
inspected nondestructively using a magnifying lens and back-
lighting every 24 hours throughout the experiment.
After the completion of testing, the stents were re-
moved from the mock arteries and visually inspected for
fractures using a high-powered (40) optical microscope.
The observers were not blinded to the identity of the stent
because each stent is immediately recognizable by its pattern.
Test samples included 30 Absolute stents (10  60
mm, n 2; 10 100 mm, n 28), 5 S.M.A.R.T. Control
Iliac Stent System stents (Cordis/Johnson & Johnson,
Miami Lakes, Fla; 9  60 mm), 9 Xceed Biliary Self-
Expanding Stent System stents (Abbott Vascular; 6  120
mm), 5 Luminexx Biliary Stents (C. R. Bard, Murray Hill,
NJ; 9  60 mm), 5 Protégé EverFlex Self-Expanding
Biliary Stent System stents (EV3, Minneapolis, MN; 6 
120 mm), and 4 LifeStent FlexStar Self-Expanding Biliary
Stent System stents (Edwards Lifesciences, Irvine, CA; 6
80 mm). A range of stent lengths and diameters were used
to reflect the range of devices used clinically. The testing
method was validated to yield consistent axial compression
across a range of stent sizes.
Assessment of fracture after repetitive in vitro
bending deformation. Repetitive bending was performed
using a specially designed bend fatigue test machine
wherein stents were housed in elastic silicone tubing with a
wall thickness of 3.0  0.2 mm (Fig 3). Stents were
deployed into the silicone tubing with an oversize ratio of
1:1.4 and at an angle of 48°. Phosphate-buffered saline
(37°  2°C) was circulated through the closed system for
the duration of the experiment. The fatigue tester was set to
cycle at 7 Hz for 10 million cycles. The stents were nonde-
structively inspected for fractures every 24 hours through-
out the experiment and at its completion.
After testing was completed, the stents were removed
Fig 2. The axial deformation fatigue testing apparatus consists of
five elastic silicone tubes, each containing a single stent. Displace-
ment consisted of 0% to 5% cyclic axial deformation (shortening).
The apparatus is designed and manufactured by Abbott Vascular.from the mock arteries and visually inspected for fracturesusing a high-powered (40) optical microscope. The ob-
servers were not blinded to the identity of the stent because
each stent is immediately recognizable by its pattern.
Test samples included 30 Absolute stents (7 56mm),
5 S.M.A.R.T. Control stents (7  60 mm), 9 Xceed stents
(6  60 mm, n/4; 6  80 mm, n/4; 6  120 mm, n/1),
5 Luminexx stents (7 60 mm), 5 Protégé EverFlex stents
(6  120 mm), and 4 LifeStent FlexStar stents (6  80
mm). A range of stent lengths and diameters were used to
reflect the range of devices used clinically. The testing
method is validated to yield consistent bending deforma-
tion across a range of stent lengths of 40 mm.
Althoughmany of these devices have been approved for
use in the arterial system in other countries, none are
approved for SFA implantation in patients within the
United States. In the United States, the S.M.A.R.T. Con-
trol device is approved for implantation in the common and
external iliac arteries; all other devices used in this study are
cleared by the United States Food & Drug Administration
for biliary tract implantation only because the safety and
efficacy for their use in the vascular system has not been
established.
Statistical analysis. Group means and standard devia-
tions were calculated using Excel software (Microsoft Corp,
Redmond, Wash).
RESULTS
Native (unstented) arterial deformation in cadav-
eric lower extremity arteries. The results of axial com-
pression of native (unstented) cadaveric lower extremity ar-
teries induced by knee and hip flexion are summarized in
Fig 3. The bending deformation fatigue testing apparatus con-
sists of multiple elastic silicone tubes, with each tube containing a
single stent. The three tubes shown loaded in the apparatus with a
bend deflection angle of 48°. The apparatus is designed and
manufactured by Abbott Vascular.Table I. Axial compression in the mid-SFA and distal-SFA/
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limbs. Large increases in the percentage of axial compression
were noted within native arteries when the leg position was
changed from neutral to 70°/20° knee/hip flexion, and from
70°/20° to 90°/90° knee/hip flexion. In the unstented fem-
oropopliteal arteries, the distal-SFA/prox-PA region ap-
peared to be the most critical area for shortening, with the
highest percent axial compression, at 23% 2%with 90°/90°
knee/hip flexion, which was more than twice the 9%  5%
observed in the mid-SFA under the same conditions.
Self-expanding stent deformation in cadaveric
lower extremity arteries. The axial compression of
100-mm self-expanding nitinol stents implanted in cadav-
eric lower extremity arteries is summarized in Table II.
Axial compression was greatest in the PA, with 6% compres-
sion observed at 70°/20° knee/hip flexion and 11% com-
pression at 90°/90°. More proximally, compression was
less, with 6% compression observed in the distal-SFA/
prox-PA (at 90°/90°) and only 3% compression observed
in the mid-SFA (at 90°/90°). For subsequent stent fatigue
testing of axial compression at walking condition, the aver-
age between the distal-SFA/prox-PA and the PA at 70/
20° knee/hip flexion was selected (5%); the PA does not
represent the intended therapeutic target, but stents placed
in the SFA often extend into the PA, where a more dynamic
range of motion is expected.
The bending deformation of 100-mm self-expanding
nitinol stents placed in cadaveric lower extremities is sum-
marized in Table III. Measurements of stent bending at
70°/20° yielded a very small deflection angle in the mid-
SFA (3°) and distal-SFA/prox-PA (11°). A 48° bending
angle test parameter was selected because it represented the
upper range of values observed in the PA at 70°/20°
knee/hip flexion.
Fracture after repetitive in vitro compression and
bending. The fracture rates of nitinol stents after in vitro
axial compression are summarized in Table IV. The highest
rates of fracture were observed in the Luminexx and
LifeStent FlexStar stents, at 80% and 50%, respectively.
Protégé EverFlex and S.M.A.R.T. Control exhibited the
lowest (0 fractures in 5 stents).
The fracture rates of nitinol stents after bending defor-
Table I. Axial compressiona of cadaveric lower extremity








Neutral, % 0 0 0
Knee/hip flexion
70°/20°, % 5  4 14  5 9  5
90°/90°, % 9  5 23  2 14  3
Distal-SFA/Prox-PA, Distal superficial femoral artery/proximal popliteal
artery; Mid-SFA, mid-superficial femoral artery; PA, popliteal artery.
aAxial compression expressed as percentage reduction in total length of
unstented vessel segment compared with neutral position expressed as
mean  SD.mation are also summarized in Table IV. The highest ratesof fracture were observed in the Luminexx, Protégé
EverFlex, and S.M.A.R.T. Control, all of which exhibited
100% fracture rates (5 of 5 stents). The lowest fracture rate
was observed in LifeStent FlexStar (0 fractures in 4 stents).
The combined number of fractures, whether associated
with axial or bending deformation fatigue testing, is also
summarized in Table IV. When axial and bending defor-
mation fatigue data were combined, the Absolute stent had
the lowest composite rate of fracture (3%).
DISCUSSION
Endovascular techniques have become important ad-
juncts in the management of atherosclerotic occlusive dis-
ease. Once amendable only to open surgical revasculariza-
tion, a wide range of lesions can now be approached
percutaneously without the need for incision and dissec-
tion. Endovascular interventions within coronary arteries
are particularly effective and have become the preferred
method of treatment for most patients with occlusive syn-
dromes of the coronary circulation.20
Endovascular intervention in the peripheral circulation
has proven more problematic. Although generally effective in
the relatively large inflow arteries of the extracranial cerebro-
vascular and iliac circulations, endovascular manipulation of
the infrainguinal arteries is technically more challenging and
Table II. Axial compressiona of 100-mm self-expanding









Neutral, % 0 0 0
Knee/hip flexion
70°/20°, % 3  2 4  1 6  4
90°/90°, % 3  3 6  3 11  5
Distal-SFA/Prox-PA, Distal superficial femoral artery/proximal popliteal
artery; Mid-SFA, mid-superficial femoral artery; PA, popliteal artery.
aAxial compression expressed as percentage reduction in implanted stent
length after knee/hip flexion compared with neutral position expressed as
mean  SD.
Table III. Bending deformationa of 100-mm










70°/20° 3°  4° 11°  12° 33°  21°
90°/90° 4°  3° 15°  14° 54°  25°
Distal-SFA/Prox-PA, Distal superficial femoral artery/proximal popliteal
artery; Mid-SFA, mid-superficial femoral artery; PA, popliteal artery.
aReported as the deflection angle (mean  SD). Any bend angle present in
the neutral position was subtracted from that at 70°/20° and 90°/90° to
give the relative change in bend angle (see text).the outcome less durable. Acceptable results can often be
s at 4
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sions,21-23 but long-term patency after endovascular recanali-
zation of more complex stenoses and occlusions in the super-
ficial femoral artery is generally about 50%.3-10
The possible explanations for the discouraging results
of infrainguinal endovascular intervention are many. The
infrainguinal circulation is characterized by long conduits
with a heavy plaque burden, high impedance outflow with
low mean flow rates, prolonged fractions of the cardiac
cycle with stagnant flow, and a tendency toward exagger-
ated bending and twisting with skeletal movement.15 This
latter phenomenon, that of repetitive external biomechani-
cal forces as stimuli for neointimal hyperplasia, is supported
by the experimental finding that the more distal lower
extremity arteries of animals generally remodel less favor-
ably compared with the coronary or iliac arteries.16,17
A variety of approaches have been suggested to en-
hance patency during peripheral endovascular intervention,
including pharmacotherapy, stenting, cryoplasty, cutting
balloon angioplasty, radiation brachytherapy, and atherec-
tomy.8,11-13,24-27 The most popular to date is stenting, as
results from a recent randomized clinical trial suggest that
routine nitinol stenting enhances both angiographic and
clinical results, especially in long, complex occlusive le-
sions.2,7,14
It is troubling to note, however, that self-expanding
stents in the SFA have shown an alarming tendency to
fracture, with rates as high as 65% in one clinical report.28
Many investigators have noted this phenomenon,1,29 and
most have ascribed it to the presence of multiple repetitive
mechanical forces exerted by the unique environment of
the SFA.1,15 Indeed, one recent clinical study of 40 con-
secutive patients treated with the Luminexx stent docu-
mented strut fracture in 28%, with more frequent oc-
currence in patients who were vigorously active and
ambulatory.30
The purpose of this study was to describe and quantify
the degree of deformation sustained by nitinol stents in the
human SFA and use these parameters to test commercially
available stents for fracture in vitro.Nitinol stents, 100 mm
in length, were implanted in cadaveric lower extremities,








Luminexx 5 4 (80)
Protégé EverFlex 5 0 (0)
S.M.A.R.T. Control 5 0 (0)
Xceed 9 2 (22)
LifeStent FlexStar 4 2 (50)
Absolute 30 1 (3)
aAxial compression fatigue testing of stents consisted of 10 million cycles at
bBending deformation fatigue testing of stents consisted of 10 million cyclewhich were then flexed to physiologic positions. Stent defor-mation was minimal in the mid-SFA but greater with more
distal implantation. For instance,with bending of both the hip
and the knee of 90°, axial stent compression in the mid-SFA
was 3%with a deflection angle of 4°.More distally, mean axial
compression of 6% with a deflection angle of 15° was noted.
Not surprisingly, the maximal amount of axial compression
(mean, 11%) and bending deformation (mean deflection an-
gle, 54°) was observed in the PA.
The degrees of deformationmeasured in stented cadav-
eric extremities as boundary conditions were used to test
the ability of a variety of commercially available stents to
withstand fracture after repetitive stress representing walk-
ing conditions in vitro. The 116 stents that were tested
were exposed to deformation 10 million times, which was
chosen as the end point to simulate roughly 10 years of
active ambulation (2739 cycles/d). The actual test was
performed in accelerated fashion (7 to 10Hz) so it could be
completed in 12 to 17 days.
The results showed a wide range in the incidence of
strut fracture in response to chronic stress in vitro, from 3%
to 90%. Some stents were more susceptible to axial stress,
whereas others fractured more readily after repetitive bend-
ing stress (Table IV). The most likely explanation is the
considerable differences in stent pattern, because stent pat-
tern has the largest impact on the amount of localized strain
experienced by a strut.31 If a macroscopic geometric
change causes a local strain in a particular design that
exceeds the material’s fatigue endurance, the material will
eventually fail and the struts will fracture.
Interestingly, clinical rates of strut fracture after intra-
vascular stent implantation have also shown a wide variabil-
ity of as high as 53% for some stents designs29 and as low as
2% for others.1,7 Moreover, the in vitro fracture results
reported here appear to correspond qualitatively to patterns
of stent fracture observed during clinical use. Further vali-
dation of the potential predictive value of these in vitro
methods awaits more extensive clinical experience in this
difficult anatomic location.
CONCLUSION
Nitinol self-expanding stents are subject to both axial
bending deformation fatigue testing
Bending deformation









5 5 (100) 10 9 (90)
5 5 (100) 10 5 (50)
5 5 (100) 10 5 (50)
9 4 (44) 18 6 (33)
4 0 (0) 8 2 (25)




5% axand bending deformation when implanted into the SFA.
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withstand chronic deformation in vitro, and their response
is highly dependent on the type of deformation applied.
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